The incidence and mortality of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) are still very high, but stem cells show some promise for its treatment. Here we found that intratracheal administration of human umbilical cord-mesenchymal stem cells (UC-MSCs) significantly improved survival and attenuated the lung inflammation in lipopolysaccharide (LPS)-induced ALI mice. We also used the proteins-chip and bioinformatics to analyze interactions between UC-MSCs treatment and immune-response alternations of ALI mice. Then we demonstrated that UC-MSCs could inhibit the inflammatory response of mouse macrophage in ALI mice, as well as enhance its IL-10 expression. We provide data to support the concept that the therapeutic capacity of UC-MSCs for ALI was primarily through paracrine secretion, particularly of prostaglandin-E2 (PGE2). Furthermore, we showed that UC-MSCs might secrete a panel of factors including GM-CSF, IL-6 and IL-13 to ameliorate ALI. Our study suggested that UC-MSCs could protect LPS-induced ALI model by immune regulation and paracrine factors, indicating that UC-MSCs should be a promising strategy for ALI/ARDS.
Protein-array of bronchoalveolar lavage fluid (BALF).
Protein-array analysis of BALF was performed using the Raybiotech TM 308 biotin label-based mouse antibody array (Raybiotech, Georgia, USA) according to the manufacturer's protocol, as the previous report 14 . The expression levels for each protein were normalized to the mean intensity of positive control in all samples and were further analyzed using a fold change ≥ 2.0 (t-test, two-tailed, p < 0.05). Differentially expressed proteins were determined by Hierarchical Clustering (Gene Cluster 3.0, Tokyo, Japan) and gene-ontology (GO) classifications analysis using the DAVID online database.
Celecoxib inhibited PGE2 synthesis in UC-MSCs. To identify the role of US-MSCs paracrine factor
PGE2, we used celecoxib (Pfizer, New York, USA) to block the PGE2 synthesis in cells as previously described 15 . US-MSCs were cultured with different concentrations of celecoxib or control (0.1% DMSO) in 10% FBS DMEM/ F12 for 48 h. The cells were then washed with PBS three times and were harvested as celecoxib-pretreated UC-MSCs (UC-MSCs −PGE2 ), in which PGE2 synthesis was inhibited. Alternatively, the UC-MSCs −PGE2 were re-cultured with new serum-free medium for 24 h, and the subsequent serum-free medium was used as the PGE2-reduced UC-MSCs conditional medium (CM −PGE2 ). ELISA test was used to analyze the efficacy of celecoxib to inhibit the PGE2 paracrine of UC-MSCs, and MTT assay was used to investigate the effect of celecoxib on the growth of UC-MSCs.
The investigations of paracrine activities of UC-MSCs. 0.5 × 10 6 UC-MSCs were cultured in 2 ml ALI mice bronchoalveolar lavage fluid (BALF), added with 2 ml DMEM/F12 for 24 h, and cytokines/chemokines secreted by UC-MSCs in culture supernatant were tested by Multiplex-ELISA arrays (Millipore, Massachusetts, USA) according to the manufacturers' instructions 16 .
Data and statistical analysis. The values are expressed as the mean ± SE. Multiple comparisons of parametric data were performed using one-way ANOVA at specific time-points (72 h) and two-way ANOVA at different time-points (0 h, 24 h, 72 h, 120 h), followed by Bonferroni multiple test between groups. The survival curves were compared with a log-rank test (Graphpad Prism5.0, California, USA). p < 0.05 was considered statistically significant.
(The other detailed Supplementary Information for Methods is presented online).
Results

UC-MSCs improve survival and attenuate lung inflammation in LPS-induced ALI mice.
We successfully isolated UC-MSCs from human Wharton's Jelly (Suppl. Fig. 1 ) and constructed a stable ALI animal model by intratracheal injection of 5 mg/kg LPS (Suppl. Fig. 2 ). The ALI mice were then transtracheally injected with UC-MSCs (0.5 × 10 6 ) after being administered LPS for 1 h (Suppl. Fig. 2a ). The survival and weight improvement of LPS-induced ALI mice treated with UC-MSCs, both in BALB/c and C57/BL6 mice (Fig. 1a,b) , indicated the significant therapeutic effects of UC-MSCs in ALI. Then we used BALB/c mice in the following experiments. The pathological damage of lung tissue from LPS-induced ALI mice treated with UC-MSCs was significantly decreased (Fig. 1c,d) , especially 72 h post-treatment. The lung injury was evidently declined, meanwhile the myeloperoxidase (MPO) activity, total protein concentration, total cell and neutrophil counts in bronchoalveolar lavage fluid (BALF) were significantly reduced, confirming that UC-MSCs attenuate the lung inflammation of LPS-induced ALI mice (Fig. 1e-h ).
UC-MSCs regulate the lung immune response of LPS-induced ALI mice.
To understand the molecules involved in US-MSCs treatment for LPS-induced ALI mice, we used a 308 protein array to analyze in the BALF (Suppl. Table 1 ). Only 32 proteins were significantly decreased, while 5 proteins were significantly increased in the LPS-induced ALI mice treated with UC-MSCs for 72 h (Fig. 2a) . The gene-ontology (GO) classifications of these 37 proteins (Suppl. were associated with the immune subtypes of macrophages (Suppl. Fig. 3a ), indicating that UC-MSCs regulate the lung immune response of LPS-induced ALI mice (Fig. 2b) . We also found that the markers of classically activated macrophages (M1, CM), TNF-α , IL-1β and IL-6 were significantly down-regulated by UC-MSCs treatment 17 . More interestingly, in 5 up-regulated proteins, 3 proteins including IL-10, CCL17 and CCL22 were reported to the markers of alternatively activated macrophages (M2, AM) 18 , especially IL-10 had been proved to be a potent anti-inflammatory cytokine to protect lung injury 19 . The results of the q-PCR (Suppl. Fig. 3b ) and ELISA assays (Fig. 2c,d ) were consistent with those of the protein microarray, suggesting that UC-MSCs treatment would polarize the lung macrophages into M2 macrophages in ALI mice. UC-MSCs modulate polarization of mouse macrophages in vivo and in vitro. To explore the effects of UC-MSCs on macrophage transition, we examined the lung macrophages in UC-MSCs-treated ALI mice by flow cytometry. The results demonstrated that the total number of lung macrophages (Maker, F4/80 and CD11b) was significantly reduced in UC-MSCs-treated ALI mice, but the IL-10 positive lung macrophages (Maker, IL-10) were up-regulated (Fig. 3a ,b, p < 0.05), indicating that UC-MSCs modulate the immune response of lung macrophages in ALI mice by promoting lung macrophages to secret more IL-10 to protect ALI mice. Therefore, UC-MSCs might alleviate the inflammatory response in ALI mice by mediating macrophages transition.
We then co-cultured LPS-stimulated mouse macrophage RAW264.7 cells with UC-MSCs to verify their relationship in vitro. The morphology of macrophages was significantly altered by LPS stimulation, including an enlarged cell body, irregular shape, and a large number of pseudopodia. Interestingly, when co-cultured with UC-MSCs, the morphology of LPS-stimulated RAW264.7 cells was presented as normal RAW264.7 cells (Fig. 3c,d ). In addition, TNF-α expression in LPS-stimulated macrophages was significantly decreased by UC-MSCs co-culture, while IL-10 expression was increased (Fig. 3e,f) , indicating that UC-MSCs promote the M2 polarization of macrophages.
UC-MSCs protect LPS-induced ALI mice via paracrine activity. Given that MSCs generate their therapeutic action through cell engraftment differentiation to directly repair injured tissues or through paracrine to facilitate self-healing of tissues 20 , we labeled UC-MSCs with DAPI in vitro and then tracked the labeled UC-MSCs in ALI mice post-injection at different times. The results showed that UC-MSCs were concentrated in the trachea 0 h post-injection, continuously infiltrated the lung parenchyma though the tracheal wall 12 h post-injection, and populated the whole lung parenchyma 24 h post-injection. However, UC-MSCs were still localized in the lung parenchyma 48 h post-injection, but the intensity of fluorescence was much lower than that of 24 h post-injection. Additionally, the DAPI-labeled UC-MSCs almost disappeared in the fluorescent microscope 72 h post-injection (Fig. 4a,b) , which indicated that the time of UC-MSCs engraftment and therapeutic effects was 24 h-48 h post-injection, suggesting that UC-MSCs secrete soluble factors responsible for relieving ALI mice, rather than differentiating target cells and replacing.
To further confirm the paracrine activity of UC-MSCs in LPS-induced ALI mice, we applied the concentrated conditioned medium from UC-MSCs to treat LPS-induced ALI mice. The results demonstrated that the conditional medium of UC-MSCs could improve the survival and body weight (Fig. 4c,d) , and ameliorate the lung injury of LPS-induced ALI mice (Fig. 4e,f) , indicating that UC-MSCs secrete soluble factors responsible for ALI mice treatment.
UC-MSCs protect ALI mice by secretion of PGE2.
MSCs are reported to release multiple paracrine factors, especially prostaglandin-E2 (PGE2), secreted from BM-MSCs, with powerful immunological regulation functions 21 , which cause macrophages to secrete IL-10 to accelerate recovery of damaged tissues 22, 23 . However, little is known about the ability of paracrine PGE2 in UC-MSCs. We analyzed the data of the gene expression array (GSE48022) from the GEO database and found that the gene expression of prostaglandin-endoperoxide synthase 2 (PTGS2/Cox-2), the rate-limiting enzyme in the biosynthesis of PGE2, is much higher in UC-MSCs than that in BM-MSCs (Suppl. Fig. 4a ), indicating the powerful ability of synthesis and secretion of PGE2 in UC-MSCs. To further verify the secretion ability of PGE2 and its biological function, we analyzed the concentration of the small molecules in the UC-MSCs conditional medium, and found that the expression of PGE2 was several folds higher than that in LPS-stimulated macrophage medium. In addition, when co-cultured with LPS-stimulated macrophages, the production of PGE2 in UC-MSCs was significantly enhanced (Suppl. Fig. 4b ), suggesting that the key role of PGE2 secreted by UC-MSCs for macrophages transition.
To confirm the effect of PGE2 secreted by UC-MSCs on macrophages, we applied celecoxib, a selective inhibitor of PGE2 biosynthesis, to approve the role of PGE2 in UC-MSCs-treated macrophages and mice. The results showed that a 1 μ mol/L concentration of celecoxib significantly reduced PGE2 expression in UC-MSCs without drug toxicity (Suppl. Fig. 4c,d ). Then we harvested the 1 μ mol/L celecoxib-pretreated UC-MSCs (UC-MSCs −PGE2 ), which PGE2 synthesis in cells was inhibited, and the conditional medium form celecoxib-pretreated UC-MSCs (UC-MSCs −PGE2
), which PGE2 concentrations was reduced. And we added them into LPS-stimulated macrophages and measured the TNF-α and IL-10 concentrations in the culture medium. The results showed that both the celecoxib-pretreated UC-MSCs (UC-MSCs −PGE2 ) and the conditional medium from celecoxib-pretreated UC-MSCs (CM −PGE2
) had a weaker capacity for inhibiting TNF-α (Suppl. Fig. 4e ) and stimulating IL-10 (Suppl. Fig. 4f ) in LPS-stimulated macrophages, indicating that UC-MSCs increased PGE2 synthesis and secretion when interacting with LPS-stimulated macrophages, resulting in the inhibitory effects on TNF-α and stimulatory effects on IL-10.
To further investigate the importance of PGE2 expression in the treatment of UC-MSCs in ALI mice, we treated mice with the celecoxib-pretreated UC-MSCs (UC-MSCs −PGE2 ) or the conditional medium from celecoxib-pretreated UC-MSCs (CM −PGE2 ) and observed the lung pathological alterations and the concentration of soluble factors in the BALF of these mice. The results (Fig. 5a-f) showed that the therapeutic effect of UC-MSCs on LPS-induced ALI mice declined with the decrease of PGE2 production, demonstrating that the rapid high expression of PGE2 secreted by UC-MSCs mediated the protection of UC-MSCs on LPS-induced ALI mice.
The paracrine molecules of UC-MSCs in relief of ALI.
To further investigate the paracrine secretions of UC-MSCs in this mouse model of ALI, we found that a panel of the molecules secreted by the stem cells was increased significantly when cultured in BALF from ALI mouse compared with control mice (Fig. 6a) . This indicated that UC-MSCs could secrete a group of paracrine (including GM-CSF, IL-6 and IL-13) responsible for ameliorating ALI in our mouse model. All the paracrine molecules are summarized in Fig. 6b . 
Discussion
In this study, we illustrated that intratracheal injection of UC-MSCs increased the survival rate of LPS-induced ALI mice and significantly reduced pulmonary inflammation. The soluble factors secreted by UC-MSCs, in particular, PGE2, GM-CSF, IL-6 and IL-13 may be the therapeutic basis of UC-MSCs for ALI.
ALI usually develops in patients with predisposing conditions that induce systemic inflammatory response, such as sepsis, pneumonia, major trauma, multiple transfusions, aspiration, and acute pancreatitis 24 . Among them, sepsis is the major etiology for ALI development, wherein Gram-negative bacteria are a prominent cause 25 . LPS, the main component of the outer membranes of Gram-negative bacteria, is the most important antigen that promotes the development of ALI 26 . Therefore, the LPS-induced animal models could highlight ways to explore mechanisms of multiple diseases and provide useful information on the discovery of novel biomarkers and drug targets 27 . In our study, the animal model induced by intra-tracheal administration of LPS successfully duplicated human ALI. The LPS-induced ALI mouse model had a classical pulmonary inflammatory state of the lungs between 48 h and 120 h, but after the administration of UC-MSCs, a decreased lung pathological lesion and inflammatory response was observed at 72 h after UC-MSCs injection, including the lung MPO activity, total protein concentration, lung neutrophil infiltration intensity, the expression of various pro-inflammation cytokines in BALF and the immune response of LPS-induced ALI mice. The results were consistent with previous studies on the beneficial effects of BM-MSCs in resolving ALI 5, 7, 28, 29 , proving that the intra-tracheal injection of UC-MSCs had protective effects in attenuating lung injury and inhibiting the lung inflammation of LPS-induced ALI mice.
Although there are therapeutic effects of MSCs for different ALI models 28 , the precise molecular mechanisms of MSCs action in ALI therapy are still unclear. Some studies found that BM-MSCs could mobilize into circulation in mice after LPS exposure, accumulate within the inflammatory site and differentiate to form endothelial and epithelium-like phenotype cells, like ACE1 and ACE2 29, 30 . Some studies postulated that soluble factors secreted by BM-MSCs played a vital role in wound repair, most likely through their anti-inflammatory, anti-apoptotic, angiogenic and immunomodulatory properties 31, 32 . To determine the UC-MSCs' location and their potential action principles, we located the DAPI-labeled UC-MSCs in ALI mice and found that UC-MSCs concentrated in the mouse lung within 24 h-48 h. Such a short period of UC-MSCs action suggested that paracrine is the dominant mechanism rather than cell differentiation and replacement in ALI repair. This hypothesis was further confirmed by UC-MSCs conditional medium ameliorating LPS-induced ALI mice. Our results revealed that the paracrine capacity of UC-MSCs had a primary functional and survival benefit in LPS-induced ALI. The secreted soluble factors in the UC-MSCs conditional medium are key for relieving ALI.
PGE2, one of the UC-MSCs paracrine factors, has demonstrated beneficial effects in LPS-induced ALI mice, which could modulate macrophage responses and attenuate the LPS-induced inflammation. Previous studies demonstrated that an intravenous injection of BM-MSCs can beneficially modulate the host immune response, by increasing the release of PGE2 from the BM-derived MSCs, acting on the EP2 and EP4 receptors of the macrophages, increasing the production of IL-10 in the macrophages and reducing inflammation 22, 23, 33 . Here, we found that UC-MSCs secrete a large amount of PGE2; however, with the decline of the PGE2 level in UC-MSCs and UC-MSCs conditional medium, both showed a lower ability to promote the production of IL-10 in LPS-stimulated RAW264.7 cells and in LPS-induced ALI mice. The increasing IL-10 level in the lungs suppresses LPS-induced ALI by reducing induction of pro-inflammatory mediators and chemokines, reducing mast-cell activation and NF-κ B activation, and down-modulating pathways generating oxidative stress 34 . Activation of MSCs impacts their therapeutic abilities in lung injury by increasing IL-10 and IL-1α levels. Thus, our data suggested that UC-MSCs-secreted PGE2 mediates the protective function of UC-MSCs in lung injury.
Moreover, we observed that UC-MSCs cultured in BALF from ALI mouse could have a high-level expression of some paracrine including GM-CSF, G-CSF, IL-6, IL-13 and others, as shown in Fig. 6a . Studies found Both GM-CSF and G-CSF belong to the family of colony-stimulating factors, playing a key role in host defense by regulating proliferation and differentiation of granulocytes and mononuclear phagocytes 35 . In response to pulmonary infection, local delivery of GM-CSF could increase the number of alveolus exudate macrophages derived from blood monocytes, to improve the host defense against microbial pathogens 36 . During recently years, the benefits of GM-CSF application have been demonstrated to protect lung injury in sepsis 37 . As for IL-6, it is a multifunctional cytokine involved in the regulation of complex cellular processes such as proliferation and differentiation, and act as a key player during immune and inflammation response 38 . Recently, IL-6 is found to promote survival of human CD11b
+ peripheral blood mononuclear cells and induce M2-type macrophage polarization 39 . In addition to IL-6, the capacity of IL-13 on the transformation of macrophages into M2 macrophages had been confirmed in many previous studies 40 . Importantly, M2 macrophages are considered to play an essential role in regulation of immune response and resolution of lung inflammation 41 . Furthermore, studies also found that MSCs could induce M2 macrophages polarization through other soluble factors, such as TGF-β 1 42 , TSG-6 43 and IDO 44 , which could get together to promote disease amelioration 45 . Therefore, we deduced that UC-MSC could modulate immune responses of macrophages against LPS-induced lung injury not just by PGE2, but rather via a panel of secretory factors, such as GM-CSF, IL-6 and IL-13 also contributed to the treatment of ALI mice.
In conclusion, our results demonstrated that UC-MSCs significantly attenuate inflammatory responses and lung injury in LPS-induced ALI mice. The protective effect on ALI was due to secreted a panel of secretory factors, suggesting that UC-MSCs could be a novel therapeutic choice for ALI.
